Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer
10.3971/j.issn.1000-8578.2023.23.0447
- VernacularTitle:抗体偶联药物在小细胞肺癌中的研究进展
- Author:
Jing HAN
1
;
Yarui CHEN
;
Song WANG
;
Quanlin GUAN
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Antibody-drug conjugates;
Small-cell lung cancer;
Research progress;
New targets
- From:
Cancer Research on Prevention and Treatment
2023;50(11):1139-1144
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates (ADCs) are novel drugs consisting of monoclonal antibodies targeting tumor-specific or tumor-associated antigens coupled with different numbers of payloads via linkers. ADCs have shown promising clinical benefits in the treatment of a variety of malignancies. Small-cell lung cancer (SCLC) is a hypo-differentiated neuroendocrine tumor with an extremely high degree of malignancy. Although SCLC is sensitive to radiotherapy and chemotherapy, it has a poor prognosis due to characteristics such as early susceptibility to metastasis and recurrence. Progress in the treatment of SCLC is very limited, and more durable and effective therapies should be developed to improve prognosis. However, the progress of SCLC-related therapeutic agents has been limited by the lack of specific molecular targets. This article reviews the basic principles and mechanisms of ADCs, highlights the research progress of relevant drugs against some targets in SCLC, and summarizes new targets that may be developed as targeted drugs.
